Clarity Pharmaceuticals is launching an investigator-initiated trial that will focus on the use of its copper-64 (Cu-64)-labeled radiopharmaceutical, Cu-64 SAR-bisPSMA, in prostate cancer.
The trial, referred to as the X-Calibur trial, will look at the safety of Cu-64 SAR-bisPSMA as well as the impact of the product on staging and clinical management of participants with prostate cancer. It will include up to 150 patients at the Urology Cancer Center and GU Research Network (GURN) in Omaha, NE, sponsored by Dr. Luke Nordquist.
